Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway

Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway

Item
http://www.wikidata.org/entity/Q26800894
Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus.Nonalcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, Natural History, Diagnosis, and Current Treatment Options.Nonalcoholic Fatty Liver Disease: Lipids and Insulin Resistance.Alisol B 23-acetate protects against non-alcoholic steatohepatitis in mice via farnesoid X receptor activation.The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans.Pharmacogenomic and personalized approaches to tackle nonalcoholic fatty liver disease.Structure of proof of concept studies that precede a nonalcoholic steatohepatitis development program.Protective effect of rimonabant, a canabinoid receptor 1 antagonist, on nonalcoholic fatty liver disease in a rat model through modulation of the hepatic expression of activin A and follistatin.Combination of Emricasan with Ponatinib Synergistically Reduces Ischemia/Reperfusion Injury in Rat Brain Through Simultaneous Prevention of Apoptosis and Necroptosis.Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches.Regulation of Mitochondrial Trifunctional Protein Modulates Nonalcoholic Fatty Liver Disease in Mice.Hepatoprotective Effects of Nonpolar Extracts from Inflorescences of Thistles Cirsium vulgare and Cirsium ehrenbergii on Acute Liver Damage in Rat.Treating fatty liver disease by modulating mitochondrial pyruvate metabolism.Pathogenesis of Nonalcoholic Steatohepatitis.Clinical endpoints and adaptive clinical trials in precirrhotic nonalcoholic steatohepatitis: Facilitating development approaches for an emerging epidemic.A nonalcoholic fatty liver disease model in human induced pluripotent stem cell-derived hepatocytes, created by endoplasmic reticulum stress-induced steatosis
P2860

Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway

Item
http://www.wikidata.org/entity/Q26800894
description
2015 nî lūn-bûn
@nan
2015 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Non-Alcoholic Steatohepatitis: ...... a Regulatory Approval Pathway
@ast
Non-Alcoholic Steatohepatitis: ...... a Regulatory Approval Pathway
@en
Non-Alcoholic Steatohepatitis: ...... a Regulatory Approval Pathway
@nl
type
label
Non-Alcoholic Steatohepatitis: ...... a Regulatory Approval Pathway
@ast
Non-Alcoholic Steatohepatitis: ...... a Regulatory Approval Pathway
@en
Non-Alcoholic Steatohepatitis: ...... a Regulatory Approval Pathway
@nl
prefLabel
Non-Alcoholic Steatohepatitis: ...... a Regulatory Approval Pathway
@ast
Non-Alcoholic Steatohepatitis: ...... a Regulatory Approval Pathway
@en
Non-Alcoholic Steatohepatitis: ...... a Regulatory Approval Pathway
@nl
P1433
P1476
P2093
P275
P2860
P2888
P304
P31
P356
P407
P433
P478
P50
P5008
P577
P5875
P6179
P698
P921
P932
P356
P1433
P1476
Non-Alcoholic Steatohepatitis: ...... a Regulatory Approval Pathway
@en
P2093
P275
P2860
P2888
P304
P31
P356
P407
P433
P478
P50
P5008
P577
P5875
P6179
P698
P921
P932